Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -36.37% is 33% below its 5-year average of -27.33%, near the low end of its 5-year range (-41.05%–-19.66%).
36.14% below its 12-month average of -26.71%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.81%.
RETURN ON ASSETS (ROA)
-36.37%
RETURN ON ASSETS (ROA) AVG TTM
-26.71%
RETURN ON ASSETS (ROA) AVG 3Y
-31.04%
RETURN ON ASSETS (ROA) AVG 5Y
-27.33%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-36.14%
CURRENT VS 3Y AVG
-17.18%
CURRENT VS 5Y AVG
-33.07%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.45%
median of 501 covered companies
CURRENT VS SECTOR MEDIAN
-37.50%
vs the sector median at left
4D Molecular Therapeutics, Inc.
Market Cap
$675.41M
Return on Assets (ROA)
-36.37%
TTM Avg
-26.71%
3Y Avg
-31.04%
5Y Avg
-27.33%
Market Cap
$688.14M
Return on Assets (ROA)
-82.36%
TTM Avg
-56.97%
3Y Avg
-52.21%
5Y Avg
-45.34%
Market Cap
$698.60M
Return on Assets (ROA)
-103.29%
TTM Avg
-79.28%
3Y Avg
-61.36%
5Y Avg
-60.54%
Market Cap
$643.37M
Return on Assets (ROA)
-37.63%
TTM Avg
-55.16%
3Y Avg
-41.63%
5Y Avg
-48.17%
Market Cap
$707.86M
Return on Assets (ROA)
-70.67%
TTM Avg
-51.05%
3Y Avg
-54.02%
5Y Avg
-55.25%
Market Cap
$642.31M
Return on Assets (ROA)
-13.75%
TTM Avg
-12.94%
3Y Avg
-23.44%
5Y Avg
-17.36%
Market Cap
$709.33M
Return on Assets (ROA)
2.24%
TTM Avg
3.98%
3Y Avg
2.51%
5Y Avg
4.09%
Market Cap
$637.59M
Return on Assets (ROA)
-7.75%
TTM Avg
-4.25%
3Y Avg
-2.93%
5Y Avg
9.76%
Market Cap
$632.76M
Return on Assets (ROA)
-23.40%
TTM Avg
-34.85%
3Y Avg
-33.75%
5Y Avg
-41.05%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $675.41M | -36.37% | -26.71% | -31.04% | -27.33% |
| Annexon, Inc. (ANNX)vs › | $688.14M | -82.36% | -56.97% | -52.21% | -45.34% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -103.29% | -79.28% | -61.36% | -60.54% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | -37.63% | -55.16% | -41.63% | -48.17% |
| Helus Pharma Inc. (HELP)vs › | $707.86M | -70.67% | -51.05% | -54.02% | -55.25% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -13.75% | -12.94% | -23.44% | -17.36% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 2.24% | 3.98% | 2.51% | 4.09% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -7.75% | -4.25% | -2.93% | 9.76% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | -23.40% | -34.85% | -33.75% | -41.05% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -59.88% | -116.93% | -132.27% | -105.87% |
ROA
-36.4%
ROE
-44.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -24.72% |
| 2024-12-31 | -28.71% |
| 2023-12-31 | -29.67% |
| 2022-12-31 | -41.05% |
| 2021-12-31 | -20.18% |
| 2020-12-31 | -19.66% |
| 2019-12-31 | -84.67% |
| 2018-12-31 | -9.85% |
| 2017-12-31 | -41.08% |
